Dan Stanton

@Dan5tanton

B2B journo focused on biopharma & bioprocessing industry. Information is not knowledge, knowledge is not wisdom. Opinions are all mine and probably not yours

Vrijeme pridruživanja: siječanj 2013.

Medijski sadržaj

  1. 3. velj

    Breaking: Catalent to buy Orgenesis' biz Masthercell for $315m - story Insider

  2. 30. sij

    Lack of good a factor for in investing $70-90m into internal PA gene therapy plant

  3. 29. sij

    Ori: Partnerships key to bring down cell therapy COGS - UK firm says its automated closed manufacturing platform can reduce autologous COGS by 60-80% and has teamed with

  4. 27. sij

    It's here! Falcon CEO Susan Nichols’ annual roundup of top events within the cell and gene therapy space in 2019, from Contains capacity, and M&A , but takes the top spot

  5. 24. sij

    Discovery Labs' newly formed CDMO in $1.2bn push to deliver capacity to cell & gene space at ex-GSK site in PA - Bioprocess Insider, from

  6. 22. sij

    received a PR claiming creation of world’s largest cell gene . Seemed pie in the sky but talk at by MLP Ventures founder Brian O’Neill behind project was inspirational and 1.6m sqft PA site could turn industry on its head. Ps he got huge cheer from a full room

    Prikaži ovu nit
  7. 22. sij

    FDA cell and gene therapy forecast ‘unlikely’ - the opinion from Phacilitate as number of commercialized therapeutics falls flat after dynamic 2017

  8. 22. sij

    All set for the 6.30am fun run in miami, and also regretting that final beer last night

    Prikaži ovu nit
  9. 21. sij

    and all set for the plenary at chaired by the legendary (though he’s a bit of a Dark Horse)

  10. 21. sij

    iovance admits TIL therapies with 22 day manufacturing process and potential gene editing added will be very expensive, though refuses to say whether it will be Kymriah expensive or Zolgensma expensive, at

  11. 21. sij

    ⁩ talks to Joan Finnegan, advocate, about the patient side of the pharma and regenerative med industry in emotional fireside chat. Too often patients are overlooked at industry conferences but not at

  12. 21. sij

    The tech of tomorrow zone at sponsored by ⁦⁩ and ⁦⁩ is shaping up nicely... looking forward to a great show

  13. 8. sij

    Takeda to Fund AI Projects at MIT as Part of New 3-Year Collaboration via

  14. 3. sij

    How process optimization brought Bivigam back - ADMA Biologics says a data driven approach was key to bringing its primary immune deficiency disease drug Bivigam back to market

  15. 31. pro 2019.

    Healthcare Tech is Here, Now We Must Learn to Manage the Data via

  16. 31. pro 2019.

    Evotec CEO Discusses Ways to Make Drug R&D Faster and Better via

  17. 24. pro 2019.

    On the first day of Christmas my leading news site gave to me, a merger based on CAR-T... Check out festive look back at 2019

  18. 19. pro 2019.

    Oxford Biomedica will keep supplying with the vectors needed to make Kymriah and other CAR-T products under a 5-year deal extension

  19. 17. pro 2019.

    Hemophilia A-OK! Roche’s $4.3bn Spark buy - There is no risk of competitive harm between Roche’s approved hemophila A monoclonal antibody and Spark’s candidates, says

  20. 16. pro 2019.

    a exclusive: WuXi Biologics establishes microbial fermentation platform after building up mammalian and services -

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·